Zacks.com on MSN16h
Biogen Partner Eisai Gets Positive CHMP Nod for Leqembi in Europe
The CHMP renders a positive opinion recommending approval for BIIB and Eisai's Leqembi for treating early Alzheimer's disease ...
Nottinghamshire Live on MSN4h
EU approves life changing 'important' Alzheimer's drug which can drastically slow onset
Lecanemab is the first treatment for Alzheimer’s disease licensed for use in Great Britain that shows some evidence of ...
Life-changing Alzheimer's drug approved for use in EU to reduce cognitive decline
A groundbreaking medication designed to delay the onset of Alzheimer's has received approval for use within the EU. The drug, ...
Business Insider23h
Biogen (BIIB) Gets a Buy from TD Cowen
TD Cowen analyst Phil Nadeau maintained a Buy rating on Biogen (BIIB – Research Report) today and set a price target of $275.00. The company’s shares closed yesterday at $164.89. According to TipRanks ...
Business Insider23h
Positive EMA Reversal Boosts Biogen’s Leqembi Prospects Despite Challenges
Analyst Michael Yee of Jefferies maintained a Buy rating on Biogen (BIIB – Research Report), retaining the price target of $250.00. Michael Yee has given his Buy rating due to a combination of factors ...
Worldwide Healthcare Trust PLC - Half-year Report
LONDON STOCK EXCHANGE ANNOUNCEMENT ...
Reuters22h
United Kingdom
category UK energy regulator approves $2.5 billion funding for new subsea cable 8:35 AM UTC · Updated ago Artificial Intelligencecategory UK must keep trade open and EU close in fragmenting world ...
PipelineReview.com23h
Eisai Receives Positive Opinion from the CHMP in the European Union for Lecanemab in Early Alzheimer’s Disease
TOKYO, Japan and CAMBRIDGE, MA, USA I November 14, 2024 I Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") and Biogen Inc. (Nasdaq: BIIB, ...